Experienced in Cholangiocarcinoma (Bile Duct Cancer)

Neesha C. Dhani

Toronto, ON, CA 
Experienced in Cholangiocarcinoma (Bile Duct Cancer)
Toronto, ON, CA 
OverviewLocationsClinical Research

Overview

Neesha Dhani practices in Toronto, Canada. Ms. Dhani is rated as an Experienced expert by MediFind in the treatment of Cholangiocarcinoma (Bile Duct Cancer). Her top areas of expertise are Pancreatic Ductal Adenocarcinoma, Ovarian Cancer, Cerebral Hypoxia, Pancreatic Cancer, and Pancreatectomy.

Her clinical research consists of co-authoring 75 peer reviewed articles and participating in 9 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, she has co-authored 2 articles in the study of Cholangiocarcinoma (Bile Duct Cancer).

Gender
Female

Locations

Toronto, ON, Canada
Other Locations
Toronto, Canada

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

9 Clinical Trials

A Phase III Randomized, Placebo-Controlled Study of Pembrolizumab (MK-3475, NSC #776864) in Addition to Paclitaxel and Carboplatin for Measurable Stage III or IVA, Stage IVB or Recurrent Endometrial Cancer
A Phase III Randomized, Placebo-Controlled Study of Pembrolizumab (MK-3475, NSC #776864) in Addition to Paclitaxel and Carboplatin for Measurable Stage III or IVA, Stage IVB or Recurrent Endometrial Cancer
Enrollment Status: Active_not_recruiting
Publish Date: October 15, 2025
Intervention Type: Other, Drug, Procedure, Biological
Study Drugs: Carboplatin, Paclitaxel, Pembrolizumab
Study Phase: Phase 3
A Phase 2 Study of XL184 (Cabozantinib) in Recurrent or Metastatic Endometrial Cancer
A Phase 2 Study of XL184 (Cabozantinib) in Recurrent or Metastatic Endometrial Cancer
Enrollment Status: Completed
Publish Date: October 01, 2025
Intervention Type: Drug, Other
Study Drug: Cabozantinib S-malate
Study Phase: Phase 2
Detection of Clinically Significant Prostate Cancer With 18F-DCFPyL PET/MR
Detection of Clinically Significant Prostate Cancer With 18F-DCFPyL PET/MR
Enrollment Status: Completed
Publish Date: June 25, 2025
Intervention Type: Procedure
Study Phase: Not Applicable
A Randomized Phase II Study of Gemcitabine, Cisplatin +/- Veliparib in Patients With Pancreas Adenocarcinoma and a Known BRCA/ PALB2 Mutation (Part I) and a Phase II Single Arm Study of Single-Agent Veliparib in Previously Treated Pancreas Adenocarcinoma (Part II)
A Randomized Phase II Study of Gemcitabine, Cisplatin +/- Veliparib in Patients With Pancreas Adenocarcinoma and a Known BRCA/ PALB2 Mutation (Part I) and a Phase II Single Arm Study of Single-Agent Veliparib in Previously Treated Pancreas Adenocarcinoma (Part II)
Enrollment Status: Active_not_recruiting
Publish Date: March 11, 2025
Intervention Type: Procedure, Drug
Study Drugs: Cisplatin, Gemcitabine, Gemcitabine Hydrochloride, Veliparib
Study Phase: Phase 2
A Phase 1 Study of SGN-STNV in Advanced Solid Tumors
A Phase 1 Study of SGN-STNV in Advanced Solid Tumors
Enrollment Status: Terminated
Publish Date: February 07, 2025
Intervention Type: Drug
Study Drug: SGN-STNV
Study Phase: Phase 1
A Phase 1a/1b Study of a Novel Anti-PD-L1 Checkpoint Antibody (LY3300054) Administered Alone or in Combination With Other Agents in Advanced Refractory Solid Tumors (Phase 1a/1b Anti-PD-L1 Combinations in Tumors-PACT)
A Phase 1a/1b Study of a Novel Anti-PD-L1 Checkpoint Antibody (LY3300054) Administered Alone or in Combination With Other Agents in Advanced Refractory Solid Tumors (Phase 1a/1b Anti-PD-L1 Combinations in Tumors-PACT)
Enrollment Status: Completed
Publish Date: September 27, 2024
Intervention Type: Drug
Study Phase: Phase 1
A Phase 1, Multicenter, Open-Label, Dose Escalation and Dose Expansion Study of SQZ-PBMC-HPV as Monotherapy and in Combination With Atezolizumab or Other Immune Checkpoint Inhibitors in HLA-A*02+ Patients With HPV16+ Recurrent, Locally Advanced or Metastatic Solid Tumors
A Phase 1, Multicenter, Open-Label, Dose Escalation and Dose Expansion Study of SQZ-PBMC-HPV as Monotherapy and in Combination With Atezolizumab or Other Immune Checkpoint Inhibitors in HLA-A*02+ Patients With HPV16+ Recurrent, Locally Advanced or Metastatic Solid Tumors
Enrollment Status: Completed
Publish Date: April 14, 2023
Intervention Type: Drug, Biological
Study Drugs: SQZ-PBMC-HPV, Atezolizumab, Ipilimumab, Nivolumab
Study Phase: Phase 1
18F-Fluoroazomycin Arabinoside (FAZA) Positron Emission Tomography/Magnetic Imaging Resonance (PET/MRI) as a Biomarker of Hypoxia in Rectal Cancer: A Pilot Study
18F-Fluoroazomycin Arabinoside (FAZA) Positron Emission Tomography/Magnetic Imaging Resonance (PET/MRI) as a Biomarker of Hypoxia in Rectal Cancer: A Pilot Study
Enrollment Status: Completed
Publish Date: August 16, 2019
A Clinical Trial of Intratumoral Hypoxia and Its Biologic Correlates in Patients Undergoing Surgical Resection of Localized Pancreatic Cancer, Using Pre-operative Administration of the Hypoxia Marker Pimonidazole.
A Clinical Trial of Intratumoral Hypoxia and Its Biologic Correlates in Patients Undergoing Surgical Resection of Localized Pancreatic Cancer, Using Pre-operative Administration of the Hypoxia Marker Pimonidazole.
Enrollment Status: Completed
Publish Date: July 30, 2018
Intervention Type: Drug
View 8 Less Clinical Trials

75 Total Publications

Multidisciplinary ambulatory management of malignant bowel obstruction (MAMBO) program in patients with advanced gynecological cancers: A prospective study.
Multidisciplinary ambulatory management of malignant bowel obstruction (MAMBO) program in patients with advanced gynecological cancers: A prospective study.
Journal: Gynecologic oncology
Published: June 22, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Ms. Dhani's expertise for a condition
ConditionClose
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile